Ductal Carcinoma In Situ-Current Management

Surgical Clinics of North America

Volumn 87, Issue 2, 2007, Pages 333-351

  O'Sullivan, Martin J ^a   Morrow, Monica ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DUCTAL CARCINOMA IN SITU; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; MASTECTOMY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SENTINEL LYMPH NODE BIOPSY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SENTINEL LYMPH NODE BIOPSY; TAMOXIFEN;

EID: 34247877709     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.01.006     Document Type: Review

References (120)

1. Rosner D., Bedwani R.N., Vana J., et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 192 2 (1980) 139-147
2. Ernster V.L., Barclay J., Kerlikowske K., et al. Incidence and treatment for ductal carcinoma in situ of the breast. JAMA 275 12 (1996) 913-918
3. Seidman H., Gelb S.K., Silverberg E., et al. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 37 (1987) 258-290
4. Rosenberg R.D., Lando J.F., Hunt W.C., et al. The New Mexico Mammography Project: screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 78 (1996) 1731-1739
5. Olivotto I.A., Kan L., d'Yachkova Y., et al. Ten years of breast screening in the screening mammography program of British Columbia. J Med Screen 7 (2000) 152-159
6. May D.S., Lee N.C., Nadel M.R., et al. The National Breast And Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women. AJR Am J Roentgenol 170 (1998) 97-104
7. May D.S., Lee N.C., Richardson L.C., et al. Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States). Cancer Causes Control 11 (2000) 697-705
8. Canada H. Organized breast cancer screening programs in Canada: 1996 report. Laboratory Centre for Disease Control, Health Canada. Minister of Public Works and Government Services Canada; 1999.
9. UK Trial of Early Detection of Breast Cancer Group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 353 (1999) 1909-1914
10. Alpers C., and Wellings S. The prevalence of carcinoma in situ in normal and cancer-associated breast. Hum Pathol 16 8 (1985) 796-807
11. Bartow S., Pathak D., Black W., et al. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. Cancer 60 11 (1987) 2751-2760
12. Bhatal P.S., Brown R.W., Lesueur G.C., et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 51 2 (1985) 271-278
13. Kramer W.M., and Rush Jr. B.F. Mammary duct proliferation in the elderly. Cancer 31 1 (1973) 130-137
14. Nielsen M., Jensen J., and Anderson J. Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women. Cancer 54 4 (1984) 612-615
15. Nielsen M., Thomsen J.L., Primdahl S., et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 56 6 (1987) 814-819
16. Wellings S.R., and Jensen H.M. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 50 5 (1973) 1111-1118
17. Pandya S., Mackarem G., Lee A.K.C., et al. Ductal carcinoma in situ: the impact of screening on clinical presentation and pathologic features. Breast J 4 (1998) 146-151
18. Silverstein M.J., Waisman J.R., Gamagami P., et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 66 1 (1990) 102-108
19. Fisher E.R., Dignam J., Tan-Chiu E., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: intraductal carcinoma. Cancer 86 3 (1999) 429-438
20. Gapstur S.M., Morrow M., and Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281 22 (1999) 2091-2097
21. Kerlikowske K., Barclay J., Grady D., et al. Risk factors for ductal carcinoma in situ. J Natl Cancer Inst 89 1 (1997) 76-82
22. Claus E.B., Stowe M., and Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93 23 (2001) 1811-1817
23. Brenin D., and Morrow M. Is mastectomy overtreatment for ductal carcinoma in situ?. Breast Cancer Res Treat 50 (1998) 28
24. Rosen P.P., and Oberman H. Tumors of the mammary gland (1993), Armed Forces Institute of Pathology, Washington, DC
25. Page D.L., and Anderson T.J. Diagnostic histopathology of the breast (1987), Churchill Livingstone, Edinburgh, Scotland
26. Moriya T., and Silverbert S.G. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 74 11 (1994) 2972-2978
27. Lennington W.J., Jensen R.A., Dalton L.W., et al. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 73 1 (1994) 118-124
28. Quinn C.M., Ostrowski J.L., Parkin G.J.S., et al. Ductal carcinoma in situ of the breast: the clinical significance of histological classification. Histopathology 30 2 (1997) 113-119
29. Sloane J.P., Amendoeira I., Apostolikas N., et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol 29 10 (1998) 1056-1062
30. Silverstein M.J., Poller D.N., Waisman J.R., et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 345 8958 (1995) 1154-1157
31. The Consensus Conference Committee. Consensus conference of the classification of ductal carcinoma in situ. Cancer 80 9 (1997) 1798-1802
32. Guidi A.J., Fischer L., Harris J.R., et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86 8 (1994) 614-619
33. Bobrow L.G., Happerfield L.C., Gregory W.M., et al. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11 3 (1994) 199-207
34. Evans A.J., Pinder S.E., Ellis I.O., et al. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB2 oncogene expression. Clin Radiol 49 8 (1994) 559-562
35. Otteson G.L., Christensen I.J., Larsen J.K., et al. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 60 3 (2000) 219-226
36. Siziopikou K.P., Prioleau J.E., Harris J.R., et al. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77 3 (1996) 499-506
37. Zafrani B., Leroyer A., Fourquet A., et al. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 11 3 (1994) 208-214
38. Nofech-Mozes S., Spayne J., Rakovitch E., et al. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol 12 5 (2005) 256-264
39. Bircan S., Kapucuoglu N., Baspinar S., et al. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 202 8 (2006) 569-576
40. Schuetz C.S., Bonin M., Clare S.E., et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66 10 (2006) 5278-5286
41. Vogl G., Dietze O., and Hauser-Kronberger C. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast. Histopathology 47 6 (2005) 617-624
42. Oliveira V.M., Piato S., and Silva M.A. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat 95 3 (2006) 235-241
43. Mylonas I., Makovitzky J., Jeschke U., et al. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25 3A (2005) 1719-1723
44. Lebrecht A., Grimm C., Euller G., et al. Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast. Int J Biol Markers 19 3 (2004) 236-239
45. Emberley E.D., Alowami S., Snell L., et al. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res 6 4 (2004) R308-R315
46. Schmid B.C., Rudas M., Rezniczek G.A., et al. CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat 84 3 (2004) 247-250
47. Lee C.H., Carter D., Philpotts L.E., et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?. Radiology 217 2 (2000) 466-470
48. Morrow M., Venta L., Stinson T., et al. Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 233 4 (2001) 537-541
49. Golub R.M., Bennett C.L., Stinson T., et al. Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms. J Clin Oncol 22 12 (2004) 2430-2437
50. Fisher B., Land S., Mamounas E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast And Bowel Project experience. Semin Oncol 28 4 (2001) 400-418
51. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N., Meijnen P., Peterse J.L., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ. Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24 21 (2006) 3381-3387
52. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 9169 (1999) 1993-2000
53. Solin L.J., Fourquet A., Vicini F.A., et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103 6 (2005) 1137-1146
54. Mirza N.Q., Vlastos G., Meric F., et al. Ductal carcinoma in situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7 9 (2000) 656-664
55. Rodrigues N., Carter D., Dillon D., et al. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 54 5 (2002) 1331-1335
56. Hiramatsu H., Bornstein B.A., Recht A., et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am 1 1 (1995) 55-61
57. Vargas C., Kestin L., Go N., et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 63 5 (2005) 1514-1521
58. Amichetti M., Caffo O., Richetti A., et al. Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. Eur J Cancer 33 10 (1997) 1559-1565
59. Arnesson L.G., Smeds S., Fagerberg G., et al. Follow-up of two treatment modalities for ductal carcinoma in situ of the breast. Br J Surg 76 7 (1989) 672-675
60. Ashikari R., Huvos A.G., and Snyder R.E. Prospective study of noninfiltrating carcinoma of the breast. Cancer 39 2 (1977) 435-439
61. Jha M.K., Avlonitis V.S., Griffith C.D., et al. Aggressive local treatment for screen-detected DCIS results in very low rates of recurrence. Eur J Surg Oncol 27 5 (2001) 454-458
62. Kinne D.W., Petrek J.A., Osborne M.P., et al. Breast carcinoma in situ. Arch Surg 124 1 (1989) 33-36
63. Schuh M.E., Nemoto T., Penetrante R., et al. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg 121 11 (1986) 1303-1307
64. Silverstein M.J. Van Nuys experience by treatment. In: Silverstein M.J. (Ed). Ductal carcinoma in situ of the breast (1997), Williams and Wilkins, Baltimore (MD) 443-448
65. Sunshine J.A., Moseley M.S., Fletcher W.S., et al. Breast carcinoma in situ: a retrospective review of 112 cases with a minimum 10-year follow-up. Am J Surg 150 1 (1985) 44-51
66. Von Rueden D.G., and Wilson R.E. Intraductal carcinoma of the breast. Surg Gynecol Obstet 158 2 (1984) 105-111
67. Ward B.A., McKhann C.F., and Ravikumar T.S. Ten-year follow-up of breast carcinoma in situ in Connecticut. Arch Surg 127 (1992) 1392-1395
68. Silverstein M.J., Lagios M.D., Martino S., et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 16 4 (1998) 1367-1373
69. Solin L.J., Fourquet A., Vicini F.A., et al. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 91 6 (2001) 1090-1097
70. Neuschatz A.C., DiPetrillo T., Steinhoff M., et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94 7 (2002) 1917-1924
71. Faverly D.R.G., Burgers L., Bult P., et al. Three-dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11 3 (1994) 193-198
72. Kuske R.R., Bean J.M., Garcia D.M., et al. Breast conservation therapy for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys 26 3 (1993) 391-396
73. Solin L.J., Recht A., Fourquet A., et al. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 68 11 (1991) 2337-2344
74. Solin L.J., Kurtz J., Fourquet A., et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14 3 (1996) 754-763
75. McCormick B., Rosen P.P., Kinne D., et al. Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 21 2 (1991) 289-292
76. Ray G.R., Adelson J., Hayhurst E., et al. Ductal carcinoma in situ of the breast: results of treatment by conservative surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 28 1 (1994) 105-111
77. Cutuli B., Cohen-Solal-le Nir C., de Lafontan B., et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 53 4 (2002) 868-879
78. Solin L.J., Fourquet A., Vicini F.A., et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 50 4 (2001) 991-1002
79. Silverstein M.J., Lagios M.D., Groshen S., et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340 19 (1999) 1455-1461
80. Schwartz G.F., Finkel G.C., Garcia J.C., et al. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 70 10 (1992) 2468-2474
81. Lagios M.D., Margolin F.R., Westdahl P.R., et al. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63 4 (1989) 618-624
82. Lagios M.D., and Silverstein M.J. Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 6 2 (1997) 385-392
83. Houghton J., George W.D., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362 (2003) 95-103
84. Wong J.S., Kaelin C.M., Troyan S.L., et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24 7 (2006) 1031-1036
85. Julian T.B., Land S., Haile S., et al. Is sentinel node biopsy in DCIS necessary?. Ann Surg Oncol 135 (2006) 11
86. Kettritz U., Rotter K., Schreer I., et al. Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study. Cancer 100 2 (2004) 245-251
87. Liberman L., Smolkin J.H., Dershaw D.D., et al. Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy. Radiology 208 (1998) 251-260
88. Brem R.F., Schoonjans J.M., Sanow L., et al. Reliability of histologic diagnosis of breast cancer with stereotactic vacuum-assisted biopsy. Am Surg 67 (2001) 388-392
89. Won B., Reynolds H.E., Lazaridis C.L., et al. Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease. AJR Am J Roentgenol 173 (1999) 227-229
90. Jackman R.J., Burbank F., Parker S.H., et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 218 (2001) 497-502
91. Klauber-DeMore N., Tan L.K., Liberman L., et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?. Ann Surg Oncol 7 9 (2000) 636-642
92. Cox C.E., Nguyen K., Gray R.J., et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?. Am Surg 67 6 (2001) 513-519
93. Mittendorf E.A., Arciero C.A., Gutchell V., et al. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg 62 2 (2005) 253-257
94. Camp R., Feezor R., Kasraeian A., et al. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J 11 6 (2005) 394-397
95. Sakr R., Barranger E., Antoine M., et al. Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol 94 5 (2006) 426-430
96. Wilke L.G., McCall L.M., Posther K.E., et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13 4 (2006) 491-500
97. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124 (2000) 966-978
98. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
99. Schwartz G.F., Giuliano A.E., and Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, (PA). Cancer 94 (2002) 2542-2551
100. Cote RJ, Peterson HF, Chaiwun B, et al. and International Breast Cancer Study Group. Role of immunohistochemical detection of lymph node metastases in management of breast cancer. Lancet 1999;354:896-900.
101. Carter B.A., Jensen R.A., Simpson J.F., et al. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 113 (2000) 259-265
102. Youngson B.J., Liberman L., and Rosen P.P. Displacement of carcinomatous epithelium in surgical breast specimens following stereotactic core biopsy. Am J Clin Pathol 103 (1995) 598-602
103. Douglas-Jones A.G., and Verghese A. Diagnostic difficulty arising from displaced epithelium after core biopsy in intracystic papillary lesions of the breast. J Clin Pathol 55 (2002) 780-783
104. Bleiweiss I.J., Nagi C.S., and Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol 24 13 (2006) 2013-2018
105. Lara J.F., Young S.M., Velilla R.E., et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 98 (2003) 2105-2113
106. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24 [abstract]. Presented at 25th Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 11-14, 2002.
107. Bur M.E., Zimarowski M.J., Schnitt S.J., et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69 5 (1992) 1174-1181
108. Poller D.N., Snead D.R., Roberts E.C., et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 68 1 (1993) 156-161
109. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
110. Holland R., and Hendriks J. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol 11 3 (1994) 181-192
111. Holland R., Hendriks J.H., Verbeek A.L., et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335 8688 (1990) 519-522
112. Morrow M., Schmidt R., and Hassett C. Patient selection for breast-conserving surgery with magnification mammography. Surgery 118 4 (1995) 621-626
113. Kearney T., and Morrow M. Effect of re-excision on the success of breast conserving surgery. Ann Surg Oncol 2 4 (1995) 303-307
114. Bazzocchi M., Zuiani C., Panizza P., et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR Am J Roentgenol 186 6 (2006) 1723-1732
115. Esserman L.J., Kumar A.S., Herrera A.F., et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 24 28 (2006) 4603-4610
116. Schouten van der Velden A.P., Boetes C., Bult P., et al. The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma. Am J Surg 192 2 (2006) 172-178
117. Bordeleau L., Rakovitch E., Naimark D.M., et al. A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92 1 (2001) 23-29
118. Katz S.J., Lantz P.M., Janz N.K., et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 23 24 (2005) 5526-5533
119. Katz S.J., Lantz P.M., and Janz N.K. Patterns and correlates of local therapy for women with ductal carcinoma in situ. J Clin Oncol 23 13 (2005) 3001-3007
120. Katz S.J., Lantz P.M., and Zemencuk J.K. Correlates of surgical treatment type for women with noninvasive and invasive breast cancer. J Womens Health Gend Based Med 10 7 (2001) 659-670